Biocon is mulling making an application to the Drugs Controller General of India (DCGI) for full marketing authorisation for itolizumab, its anti-CD-6 IgG1 monoclonal antibody drug used in COVID-19 treatment. This would make itolizumab the first medicine to have full marketing authorisation for use by COVID-19 patients, Business Standard has reported.
“We expect results from the phase 4 study on itolizumab by the end of this quarter. This would be real-world data from around 300 patients,” Arun Chandavarkar, Managing Director of Biocon Biologics told the publication.
News source:- Moneycontrol